Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $127.0 million.

  • Century Therapeutics' Cash & Equivalents fell 4711.63% to $127.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.0 million, marking a year-over-year decrease of 4711.63%. This contributed to the annual value of $212.6 million for FY2024, which is 1722.14% down from last year.
  • Century Therapeutics' Cash & Equivalents amounted to $127.0 million in Q3 2025, which was down 4711.63% from $152.3 million recorded in Q2 2025.
  • Century Therapeutics' 5-year Cash & Equivalents high stood at $260.4 million for Q2 2024, and its period low was $46.8 million during Q1 2024.
  • In the last 4 years, Century Therapeutics' Cash & Equivalents had a median value of $126.0 million in 2022 and averaged $141.1 million.
  • In the last 5 years, Century Therapeutics' Cash & Equivalents tumbled by 5033.05% in 2023 and then surged by 33410.24% in 2024.
  • Century Therapeutics' Cash & Equivalents (Quarter) stood at $84.3 million in 2022, then soared by 204.72% to $256.8 million in 2023, then fell by 17.22% to $212.6 million in 2024, then plummeted by 40.27% to $127.0 million in 2025.
  • Its Cash & Equivalents was $127.0 million in Q3 2025, compared to $152.3 million in Q2 2025 and $180.1 million in Q1 2025.